BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

AccurEdit’s ART001 Becomes First China-Developed Gene Editing Therapy to Receive FDA RMAT Designation

AccurEdit Therapeutics announced that its internally developed in vivo gene editing therapy ART001 has been granted a Regenerative Medi...

May 30, 2025 | News

Teddy Laboratory and LabConnect Forge Global Lab Alliance to Accelerate Drug Development

Teddy Laboratory, a subsidiary of Tigermed, officially signed a strategic cooperation agreement with LabConnect, LLC, a global leader in central labor...

May 30, 2025 | News

Eisai’s DAYVIGO® Approved in China to Treat Insomnia, Targeting Over 170 Million Adults

Eisai Co., Ltd. announced that the in-house-discovered and developed orexin receptor antagonist DAYVIGO® (generic name: lemborexant) has been app...

May 29, 2025 | News

RemeGen’s Telitacicept Approved in China as First Dual-Target Biologic for Generalized Myasthenia Gravis

RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Produc...

May 28, 2025 | News

Zylox-Tonbridge Secures First Southeast Asia Approval for ZYLOX Unicorn™ Vascular Closure Device in Indonesia

Zylox-Tonbridge Medical Technology Co., Ltd. ("Zylox-Tonbridge" or the "Company") announced that its proprietary ZYLOX Unicorn™ Vascular Closure Devi...

May 27, 2025 | News

Avenzo Therapeutics and Duality Biotherapeutics Gain FDA Clearance for EGFR/HER3 Bispecific ADC AVZO-1418/DB-1418

Duality Biotherapeutics ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-gen...

May 26, 2025 | News

UniXell Biotech Initiates China’s First iPSC-Based Cell Therapy Trial for Parkinson’s Disease

Shanghai UniXell Biotechnology Co., Ltd. (UniXell Biotech), a biotech company dedicated to innovative cell therapies, announced the successful first admini...

May 26, 2025 | News

Porton Advanced and TongEYE Partner to Accelerate iPSC-Derived Cell Therapy for Blinding Eye Diseases

Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleas...

May 23, 2025 | News

DualityBio and Avenzo Receive FDA IND Clearance for Novel EGFR/HER3 Bispecific ADC

Duality Biotherapeutics partner Avenzo Therapeutics, Inc. a clinical-stage biotechnology company developing next-generation oncology therapies, announced c...

May 23, 2025 | News

Kelun-Biotech's Fourth Indication for ADC sac-TMT Accepted for Priority Review in China

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new indication application (the "Application") for the Company's trophob...

May 22, 2025 | News

Minghui Doses First Patient in Phase II Trial of PD-1xVEGF Bispecific and TROP-2 ADC Combo for Advanced NSCLC

Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, announced that ...

May 21, 2025 | News

Antengene and MSD Enter Global Clinical Collaboration to Evaluate ATG-022 and KEYTRUDA® Combo in Solid Tumors

Antengene Corporation Limited , a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercial...

May 21, 2025 | News

Pfizer Strikes $1.25B Ex-China Licensing Deal With China’s 3SBio for Cancer Antibody SSGJ-707

Pfizer Inc. announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutic...

May 20, 2025 | News

Porton Advanced Partners with Hualong Biological to Accelerate Multi-Activated T Cell Therapy Development

Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleas...

May 20, 2025 | News

Stay Connected